Cend Therapeutics, spin-out company of BICI's sponsored research project "iRGD targeted drug delivery system for precise tumor diagnosis and treatment" has announced the merger with Caladrius Biosciences on September 15, 2022. The merged company will now operate as Lisata Therapeutics, Inc. and will commence trading on The Nasdaq Capital Market under the ticker symbol “LSTA”.

For detailed press release announcement, please go to https://ir.caladrius.com/news-releases/news-release-details/caladrius-biosciences-and-cend-therapeutics-announce-closing